News | September 10, 2025
Sirio secures TGA GMP certification to support strategic growth in Australia
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The facility has been designed with a dual focus on efficiency and sustainability
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Subscribe To Our Newsletter & Stay Updated
